Aurora Cannabis Inc. has confirmed its openness to considering a bid from a U.S. cannabis company looking to acquire the Edmonton-based company. The announcement of forming a special committee to review the unsolicited offer came shortly after Curaleaf Holdings Inc. disclosed its intentions to acquire all shares of Aurora.
Should the acquisition be successful, it would result in the formation of a unified cannabis entity with operations spanning 17 countries across Europe, North America, and various other global markets, as stated by Curaleaf. The Connecticut-headquartered firm, listed on the Toronto Stock Exchange, shared that it decided to make its proposal public following unsuccessful attempts to engage in private negotiations with Aurora’s leadership.
Curaleaf expressed disappointment in Aurora’s board for declining to participate in discussions after Curaleaf’s CEO, Boris Jordan, sent a formal letter of intent on June 23 outlining the acquisition proposal. Despite sending a follow-up letter on July 7, Aurora allegedly showed reluctance to engage in meaningful conversations so far.
In response, Jordan emphasized Curaleaf’s readiness to collaborate with Aurora’s board to advance the proposed transaction. Curaleaf aims to swiftly move towards a definitive agreement, highlighting the significant premium offered, compelling strategic rationale, and the need to avoid further delays.
Curaleaf has put forward a proposal to compensate Aurora shareholders with $4 US per share, in addition to $0.75 US in cash for each Aurora share. Aurora acknowledged receiving letters from Curaleaf on June 23 and July 7, with the latter containing financial terms, though specifics on the cash and share distribution were reportedly missing according to Aurora.
Contrary to Curaleaf’s claim of refusal to engage, Aurora stated that its lead independent director maintained communication with Curaleaf’s CEO as of July 24, emphasizing Aurora’s commitment to executing its business plan in the short to medium term. A special committee comprising independent directors will now assess the proposal’s viability and alignment with stakeholders’ interests, with no assurance of a finalized agreement.
While acknowledging Curaleaf’s interest, analysts from TD Cowen expressed reservations about the offer undervaluing Aurora’s long-term growth potential. They highlighted Aurora’s market leadership in medical cannabis, diverse product portfolio, robust financial position, and adeptness in navigating international regulations as factors that could drive increased value over time.
Jordan emphasized the merger’s potential to unlock value by leveraging Curaleaf’s global distribution network alongside Aurora’s prominent international medical cannabis presence and production capabilities. The combined revenue of both companies exceeded $1.5 billion US in the past year, with Curaleaf anticipating annual cost synergies of at least $40 million US from the proposed takeover.
The envisioned merger is seen as mutually beneficial for Curaleaf and Aurora shareholders, offering an opportunity for Aurora investors to engage in a more diversified global platform and capitalize on favorable U.S. regulatory trends.